KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients | PNAS
Visualisation of the action of imatinib at the KIT receptor | Download Scientific Diagram
A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors - ScienceDirect
The KIT receptor tyrosine kinase. (A) C-KIT mutations occur in 80 –90%... | Download Scientific Diagram
Computational Analysis of the Binding Specificity of Gleevec to Abl, c-Kit, Lck, and c-Src Tyrosine Kinases | Journal of the American Chemical Society
For How Long Should Adjuvant Therapy for Gastrointestinal Stromal Tumors (GIST) Be Administered?
Frontiers | Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap
Chemical structure of imatinib and its binding modes to c-Kit and Abl.... | Download Scientific Diagram
Primary Hepatic Extra-gastrointestinal Stromal Tumors: Molecular Pathogenesis, Immunohistopathology, and Treatment
EPOS™
Using Imatinib for Adjuvant Treatment after Resection of Kit-positive GIST - The ASCO Post
Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27KIP1 as a consequence of c-Abl inhibition - ScienceDirect
c-キッ阻害 | c-Kit Inhibition
A novel anti‐c‐Kit antibody–drug conjugate to treat wild‐type and activating‐mutant c‐Kit‐positive tumors - Kim - 2022 - Molecular Oncology - Wiley Online Library
Role and significance of c-KIT receptor tyrosine kinase in cancer: A review | Biomolecules and Biomedicine
The Proto-oncogene c-Kit Inhibits Tumor Growth by Behaving as a Dependence Receptor - ScienceDirect
Journal of Biomedical and Pharmaceutical Research
Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress
Cancer drug gets a makeover | News | Chemistry World
Imatinib - Wikipedia
Frontiers | Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours | British Journal of Cancer
IJMS | Free Full-Text | Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
